Orion Portfolio Solutions LLC Sells 742 Shares of Illumina, Inc. (NASDAQ:ILMN)

Orion Portfolio Solutions LLC decreased its position in Illumina, Inc. (NASDAQ:ILMNGet Rating) by 7.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,146 shares of the life sciences company’s stock after selling 742 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Illumina were worth $1,686,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. Asset Dedication LLC increased its holdings in Illumina by 75.0% in the 1st quarter. Asset Dedication LLC now owns 77 shares of the life sciences company’s stock worth $28,000 after buying an additional 33 shares in the last quarter. Farmers & Merchants Investments Inc. purchased a new stake in Illumina in the 1st quarter valued at about $30,000. Tcwp LLC purchased a new position in shares of Illumina in the 1st quarter valued at $31,000. WASHINGTON TRUST Co acquired a new stake in Illumina during the 1st quarter worth about $35,000. Finally, Riverview Trust Co acquired a new position in shares of Illumina in the 1st quarter valued at about $37,000. 86.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Atlantic Securities lowered their price target on shares of Illumina to $190.00 in a research report on Monday, August 15th. Stifel Nicolaus lowered their price target on Illumina from $480.00 to $300.00 and set a “buy” rating on the stock in a report on Friday, August 12th. Morgan Stanley cut their price objective on shares of Illumina from $350.00 to $240.00 and set an “equal weight” rating for the company in a research report on Friday, August 12th. Barclays lowered their target price on shares of Illumina to $130.00 in a report on Monday, August 15th. Finally, Robert W. Baird reduced their price target on shares of Illumina from $306.00 to $215.00 in a research report on Friday, August 12th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Illumina has an average rating of “Hold” and a consensus price target of $257.27.

Illumina Price Performance

ILMN stock opened at $193.49 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.00 and a quick ratio of 0.82. Illumina, Inc. has a 1-year low of $173.45 and a 1-year high of $436.95. The business’s 50 day simple moving average is $206.99 and its 200 day simple moving average is $247.75.

Illumina (NASDAQ:ILMNGet Rating) last released its earnings results on Thursday, August 11th. The life sciences company reported $0.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.63 by ($0.06). Illumina had a positive return on equity of 5.61% and a negative net margin of 0.43%. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.22 billion. During the same period last year, the company posted $1.87 earnings per share. The business’s revenue for the quarter was up 3.2% compared to the same quarter last year. As a group, analysts expect that Illumina, Inc. will post 2.83 EPS for the current fiscal year.

Insider Transactions at Illumina

In related news, SVP Alexander Aravanis sold 539 shares of the stock in a transaction on Thursday, July 7th. The shares were sold at an average price of $200.00, for a total transaction of $107,800.00. Following the transaction, the senior vice president now directly owns 3,346 shares of the company’s stock, valued at $669,200. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.13% of the stock is owned by corporate insiders.

About Illumina

(Get Rating)

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Further Reading

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMNGet Rating).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.